We have previously reported on the Risk Evaluation and Mitigation Strategy (REMS) program, its effect on generic development, and the FDA’s guidance on how to prevent brands from using the REMS program to block generic entry. For an overview of REMS click here. On July 4, 2018, the Maine legislature enacted…